Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegipanermin - INmune Bio

Drug Profile

Pegipanermin - INmune Bio

Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTM

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; Xencor
  • Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
  • Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Mild cognitive impairment
  • Phase I Major depressive disorder; Non-alcoholic steatohepatitis
  • No development reported Neurodegenerative disorders; Solid tumours
  • Discontinued COVID-19 respiratory infection; Parkinson's disease

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in Australia (SC, Injection)
  • 28 Jun 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (SC, Injection)
  • 22 Jun 2022 INmune has patent protection for pegipanermin for treating diseases of the central nervous system in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top